Christopher T. Giordano
2022
In 2022, Christopher T. Giordano earned a total compensation of $667.3K as President and Chief Executive Officer at Tenax Therapeutics, a 22% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $144,750 |
|---|---|
| Option Awards | $104,296 |
| Salary | $386,000 |
| Other | $32,286 |
| Total | $667,332 |
Giordano received $386K in salary, accounting for 58% of the total pay in 2022.
Giordano also received $144.8K in non-equity incentive plan, $104.3K in option awards and $32.3K in other compensation.
Rankings
In 2022, Christopher T. Giordano's compensation ranked 3,869th out of 5,760 executives tracked by ExecPay. In other words, Giordano earned more than 32.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,869 out of 5,760 | 33rd |
Division Manufacturing | 2,189 out of 3,136 | 30th |
Major group Chemicals And Allied Products | 1,059 out of 1,422 | 26th |
Industry group Drugs | 994 out of 1,323 | 25th |
Industry Pharmaceutical Preparations | 728 out of 969 | 25th |
Source: SEC filing on April 28, 2023.
Giordano's colleagues
We found two more compensation records of executives who worked with Christopher T. Giordano at Tenax Therapeutics in 2022.